Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Seattle, Washington

5 studies are recruiting for non-small cell lung cancer (nsclc) in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Swedish Cancer Institute, Seattle, Washington
    Locations
    20 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07277413 on ClinicalTrials.gov

  2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  3. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpro…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Research Center, Seattle, Washington
    Locations
    93 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06162221 on ClinicalTrials.gov

  4. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Virginia Mason Medical Center, Seattle, Washington
    Locations
    21 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

  5. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    17 in total
    Run by
    Nurix Therapeutics, Inc.

    See if you can join NCT05107674 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.